Recent analyses on retatrutides, a dual agonist for GLP-1 and glucose-dependent insulinotropic polypeptide, demonstrate encouraging findings in addressing obesity and type 2 glucose intolerance. Initial data from clinical trials show notable diminutions in body bulk and bettered glucose regulatio